Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Literature DB >> 17668161

[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Abstract

All currently available therapeutic options for multiple sclerosis have to be administered parenterally. Several oral substances are currently in the late clinical development stage. One of them, FTY720 (also known as fingolimod) is highlighted in this review. The biological effects of FTY720 are presented as well as animal data and first clinical data from a phase II trial in multiple sclerosis patients. The effects of FTY720 are based on an innovative approach and apparently target several key elements in the pathogenesis of multiple sclerosis. The first clinical data with FTY720 show very promising results, with a relapse reduction of over 50% compared to placebo and an acceptable safety profile. These results currently await confirmation in two international phase III studies which are recruiting patients worldwide.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17668161 DOI： 10.1007/s00115-007-2298-9

Source DB: PubMed Journal: Nervenarzt ISSN： 0028-2804 Impact factor: 1.214

66 in total

1. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.

Authors: S Kurose; E Ikeda; M Tokiwa; N Hikita; M Mochizuki
Journal: Exp Eye Res Date: 2000-01 Impact factor: 3.467

2. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors: Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal: Science Date: 2002-03-28 Impact factor: 47.728

3. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.

Authors: Elzbieta Sawicka; Claudia Zuany-Amorim; Corinne Manlius; Alexandre Trifilieff; Volker Brinkmann; David M Kemeny; Christoph Walker
Journal: J Immunol Date: 2003-12-01 Impact factor: 5.422

4. Sphingosine 1-phosphate analogs as receptor antagonists.

Authors: Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal: J Biol Chem Date: 2004-12-08 Impact factor: 5.157

5. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

Authors: K Chiba; Y Yanagawa; Y Masubuchi; H Kataoka; T Kawaguchi; M Ohtsuki; Y Hoshino
Journal: J Immunol Date: 1998-05-15 Impact factor: 5.422

6. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.

Authors: M Salvadori; K Budde; B Charpentier; J Klempnauer; B Nashan; L M Pallardo; J Eris; F P Schena; U Eisenberger; L Rostaing; A Hmissi; S Aradhye
Journal: Am J Transplant Date: 2006-12 Impact factor: 8.086

7. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.

Authors: Helio Tedesco-Silva; Mark D Pescovitz; Diane Cibrik; Michael A Rees; Shamkant Mulgaonkar; Barry D Kahan; Kristene K Gugliuzza; P R Rajagopalan; Ronaldo de M Esmeraldo; Hélène Lord; Maurizio Salvadori; Jennifer M Slade
Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939

[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

1. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.

2. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

3. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.

4. Sphingosine 1-phosphate analogs as receptor antagonists.

5. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

6. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.

7. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.

8. Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720.

9. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors.

10. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

1. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.